Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CT-1190B
- Development stage
- Phase 2
- Lead developer
- CARsgen Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CT-1190B is an investigational chimeric antigen receptor T-cell (CAR-T) therapy developed for the treatment of autoimmune diseases and certain hematologic malignancies. It is currently in Phase 1 clinical trials, with primary indications including moderate to severe refractory systemic lupus erythematosus (SLE), refractory/progressive systemic sclerosis (SSc), and relapsed/refractory B-cell lymphoma. The therapy involves engineering a patient's own T cells to express a CAR targeting specific disease-related antigens, enabling targeted immune-mediated destruction of pathogenic cells. The drug was initially developed by Shanghai Tongji Hospital and is being actively developed in collaboration with CARsgen Therapeutics[1][2][3][4][7].
02
Targets
Beyond the preview
Go deeper on CT-1190B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CT-1190B.